Clinical trials: Pulmonary Artery Hypertension
Hypertension, Pulmonary
Catheter Denervation of Pulmonary Arteries in Treatment of IPAH & SPAH
The aim of research proposal is to assess and compare the safety and efficacy of radiofrequency denervation of pulmonary arteries on decrease in pulmonary vascular resistance and mean pulmonary artery pressure (MPAP) in 20…
- Trial name
- CADOPA (NCT02403908)
- Testing
- nMARQ Circular and Crescent catheters
- Where
- Croatia
- Volunteers
- 60 people
- Sponsor
- Clinical Hospital Centre Zagreb
Pulmonary Arterial Hypertension (PAH)
Effects of UE Aerobic Exercise on Exercise Capacity and PA in Patients With Pulmonary Arterial Hypertension.
Group A will be training group and group B will be control group. Deep breathing exercises will be done as baseline treatment in both groups.
- Trial name
- NCT05947240
- Testing
- aerobic exercises, active alternating movements for the upper limbs
- Where
- Pakistan
- Volunteers
- 26 people
- Sponsor
- Riphah International University
Pulmonary Arterial Hypertension
Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension
The study was conducted as a placebo-controlled, randomized, 22-week double-blind study which included a dose titration period. An additional transition period occurred for those patients who elected to enroll into the open-label…
- Trial name
- NCT02279160
- Testing
- APD811
- Where
- 35 sites in United States, Australia and 7 more
- Volunteers
- 61 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
IMPAHCT: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial is a Phase 2b/Phase 3 study to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in patients with Pulmonary Arterial Hypertension…
- Trial name
- IMPAHCT (NCT05036135)
- Testing
- AV-101
- Where
- 128 sites in United States, Argentina and 24 more
- Volunteers
- 202 people
- Sponsor
- Aerovate Therapeutics
Muscle Weakness, Pulmonary Arterial Hypertension
Transforming Growth Factor Beta Signalling in the Development of Muscle Weakness in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a disease that causes raised blood pressure in blood vessels that pick up oxygen from the lungs. It has a life expectancy similar to some cancers.
- Trial name
- NCT01847716
- Where
- United Kingdom
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Home-based Inspiratory Muscle Training in Pulmonary Hypertension
The main objective of this study is to determine whether an 8-week inspiratory muscle training (IMT) programme, delivered at home through telerehabilitation, improves ventilatory efficiency (VE/VCO2 slope) compared with a sham…
- Trial name
- SLOPE-PH (NCT07917416)
- Testing
- Inspiratory muscle training
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Universidad Complutense de Madrid
Pulmonary Arterial Hypertension
An Open-Label Extension Trial of UT-15C Sustained-release (SR) in Subjects With Pulmonary Arterial Hypertension
This study provided/continued to provide oral treprostinil (UT-15C SR; treprostinil diethanolamine) to eligible subjects who participated in Studies TDE-PH-202, TDE-PH-203, TDE-PH-205, TDE-PH-301, TDE-PH-302, and TDE-PH-308.
- Trial name
- FREEDOM-EXT (NCT01027949)
- Testing
- Oral Treprostinil
- Where
- 134 sites in United States, Australia and 18 more
- Volunteers
- 894 people
- Sponsor
- United Therapeutics
Heart Defects, Congenital, Pulmonary Arterial Hypertension
Genes Associated With Development of Pulmonary Arterial Hypertension in Patients With Congenital Shunt Lesions
Pulmonary arterial hypertension (PAH) in patients with congenital heart disease (CHD) is associated with considerable morbidity and even mortality.
- Conditions
- Heart Defects, Congenital, Pulmonary Arterial Hypertension, Genetic Testing
- Trial name
- NCT02691689
- Testing
- Genetic testing
- Where
- Belgium
- Volunteers
- 21 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pulmonary Arterial Hypertension, Healthy
Right Ventricular Metabolism in Pulmonary Arterial Hypertension
The purpose of this study is to use non-invasive imaging to determine the metabolic phenotype of the right ventricle in patients with pulmonary arterial hypertension across a spectrum of disease severity.
- Trial name
- NCT02763735
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess Safety and Efficacy of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
A phase 3, randomized, double-blind, placebo-controlled study to assess safety and efficacy of ambrisentan in subjects with pulmonary arterial hypertension.
- Trial name
- NCT00423202
- Testing
- ambrisentan
- Volunteers
- 186 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension, Renal Dysfunction
The Effect of Renal Impairment on the Pharmacokinetics of Oral Treprostinil
This is a single-center, open-label, single-dose evaluation of 1 mg UT-15C SR pharmacokinetics, safety, and tolerability in subjects with normal, mild, moderate and end stage renal disease (ESRD; on dialysis).
- Trial name
- NCT01131845
- Testing
- UT-15C SR (treprostinil diethanolamine)
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Eisenmenger Quality Enhancement Research Initiative
Eisenmenger Quality Enhancement Research Initiative (QuERI) is a multi-center, observational, US-based longitudinal program, with enrollment of consecutive Eisenmenger patients who meet enrollment.
- Trial name
- ES-QuERI (NCT01623492)
- Testing
- Subjects with diagnosis of Eisenmenger Syndrome
- Volunteers
- 193 people
- Sponsor
- Actelion
Essential Hypertension
Physical Activity, Air Pollution, and High Blood Pressure
The investigators are investigating the effects of traffic-related air pollution (TRAP) on the cardiovascular and pulmonary response to exercise in patients with hypertension using a real world randomized, crossover study design.
- Trial name
- NCT05092672
- Testing
- Exercise
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- University of British Columbia
Pulmonary Hypertension
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
This study is an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who are currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or…
- Trial name
- FREEDOM-C2 (NCT00887978)
- Testing
- UT-15C SR
- Where
- 62 sites in United States, Belgium and 10 more
- Volunteers
- 310 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension (PAH)
A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag
This study will look at safety and tolerability of LIQ861 (treprostinil) inhalation powder in adults with pulmonary arterial hypertension (PAH, WHO Group 1) who switch from selexipag, a medicine taken by mouth, to treprostinil, a…
- Trial name
- NCT07759804
- Testing
- LIQ861 (treprostinil) inhalation powder
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Liquidia Technologies, Inc.
Pulmonary Arterial Hypertension
Evaluate The Clinical Effectiveness, Safety And Tolerability Of Sildenafil Used In Doses ≥20mg TID For The Treatment Of Pulmonary Arterial Hypertension
The objective of this observational study is to gain clinical insight on the actual use of sildenafil citrate (Revatio™) for the treatment of pulmonary arterial hypertension (PAH).
- Trial name
- NCT01365585
- Testing
- sildenafil citrate
- Where
- 2 sites in Germany, Ireland
- Volunteers
- 227 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
Safety and Efficacy of BIA 5-1058 in PAH
This study aims to assess the safety and tolerability of the individual highest tolerated zamicastat doses, achieved in the study BIA-51058-201, during long-term treatment in Pulmonary Arterial Hypertension (PAH) disease.
- Trial name
- NCT06009185
- Testing
- Oral zamicastat
- Where
- 11 sites in Austria, Germany and 4 more
- Volunteers
- 20 people
- Sponsor
- Bial - Portela C S.A.
Hypertension, Pulmonary
Multidisciplinary Collaboration Care in Pulmonary Arterial Hypertension (PAH)
Pulmonary arterial hypertension (PAH) is a severe pulmonary vascular affection, which treatment has evolved in the last few years, improving quality of life. However, adherence to treatment has not been assessed in such patients.
- Trial name
- ETHAP (NCT01038284)
- Testing
- Patient education, Data collection
- Where
- 11 sites in France
- Volunteers
- 101 people
- Sponsor
- University Hospital, Grenoble
Pulmonary Arterial Hypertension
Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide
The purpose of this study is: To assess the effect of BIA 5 1058 400 mg on furosemide pharmacokinetics (PK). To assess the effect of furosemide 40 mg on the PK of BIA 5 1058.
- Trial name
- NCT07173738
- Testing
- BIA 5-1058, Furosemide, BIA 5-1058 and Furosemide
- Where
- United Kingdom
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Pulmonary Arterial Hypertension
Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)
This is a placebo-controlled, double-blind, phase II clinical study to evaluate the efficacy and safety of Udenafil in patient with Pulmonary Arterial Hypertension(PAH).
- Trial name
- NCT01553721
- Testing
- udenafil
- Where
- 9 sites in South Korea
- Volunteers
- 63 people
- Sponsor
- Dong-A ST Co., Ltd.